Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2008 2
2009 5
2010 3
2011 8
2012 14
2013 14
2014 26
2015 53
2016 65
2017 81
2018 79
2019 94
2020 121
2021 26
Text availability
Article attribute
Article type
Publication date

Search Results

523 results
Results by year
Filters applied: . Clear all
Page 1
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Overall survival was significantly longer in the blinatumomab group than in the chemotherapy group. The median overall survival was 7.7 months in the blinatumomab group and 4.0 months in the chemotherapy group (hazard ratio for death with blinatumomab vs. che …
Overall survival was significantly longer in the blinatumomab group than in the chemotherapy group. The median overall survival was 7 …
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Foà R, et al. N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. The primary end point was a sustained molecular response in the bone marrow after this treatment. ...At the end of dasatinib induction therapy (day 85), 29% of the patients had a mole …
Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. The primary end point was a sustained molec …
A review of blinatumomab, a novel immunotherapy.
Newman MJ, Benani DJ. Newman MJ, et al. J Oncol Pharm Pract. 2016 Aug;22(4):639-45. doi: 10.1177/1078155215618770. Epub 2015 Nov 24. J Oncol Pharm Pract. 2016. PMID: 26607163 Review.
Blinatumomab is a novel bispecific CD19-directed CD3 T-cell engager recently approved for the treatment of relapsed or refractory Ph-negative acute lymphoblastic leukemia in adults. ...Clinical controversies with blinatumomab include use in patients with Ph-positive
Blinatumomab is a novel bispecific CD19-directed CD3 T-cell engager recently approved for the treatment of relapsed or refractory Ph-
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Gökbuget N, et al. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Blood. 2018. PMID: 29358182 Free PMC article. Clinical Trial.
In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (10(-3)) received blinatumomab 15 g/m(2) per day by continuous IV infusion for up to 4 cycles. ...The primary end point was complete MRD response status after …
In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (10(-3)) received blina
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME, Bargou R. Goebeler ME, et al. Leuk Lymphoma. 2016 May;57(5):1021-32. doi: 10.3109/10428194.2016.1161185. Epub 2016 Apr 6. Leuk Lymphoma. 2016. PMID: 27050240 Review.
Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). ...Ongoing and future trials will contribute to further optimization of blinatumomab-based T cell therapy and have to show that integrati
Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). ...O
Recent advances on blinatumomab for acute lymphoblastic leukemia.
Zhao J, Song Y, Liu D. Zhao J, et al. Exp Hematol Oncol. 2019 Nov 6;8:28. doi: 10.1186/s40164-019-0152-y. eCollection 2019. Exp Hematol Oncol. 2019. PMID: 31709129 Free PMC article. Review.
Tyrosine kinase inhibitors, antibody-drug conjugates and chimeric antigen receptor T cell therapy are changing the therapy landscape for B- ALL. Blinatumomab, a bi-specific T cell engager, has been approved for patients with relapsed/refractory and minimal residual disease …
Tyrosine kinase inhibitors, antibody-drug conjugates and chimeric antigen receptor T cell therapy are changing the therapy landscape for B- …
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L. von Stackelberg A, et al. J Clin Oncol. 2016 Dec 20;34(36):4381-4389. doi: 10.1200/JCO.2016.67.3301. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27998223 Clinical Trial.
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. ...Blinatumomab may represent an important new treatment option in this setting, requiring further investigation in curative indications....
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. ...Blinatumomab
Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Stein A, Franklin JL, Chia VM, Arrindell D, Kormany W, Wright J, Parson M, Amouzadeh HR, Choudhry J, Joseph G. Stein A, et al. Drug Saf. 2019 May;42(5):587-601. doi: 10.1007/s40264-018-0760-1. Drug Saf. 2019. PMID: 30565020 Free PMC article. Review.
The key risks associated with blinatumomab treatment include cytokine release syndrome, neurotoxicity, and medication errors. Here, we review the benefits and risks of blinatumomab treatment and describe how these risks can be mitigated....
The key risks associated with blinatumomab treatment include cytokine release syndrome, neurotoxicity, and medication errors. Here, w …
Blinatumomab: a historical perspective.
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Nagorsen D, et al. Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
A highly promising new drug candidate in late-stage clinical development for treatment of B cell malignancies is blinatumomab (MT103 or AMG 103). This bispecific antibody construct has dual specificity for CD19 and CD3 and belongs to the class of bispecific T cell engager …
A highly promising new drug candidate in late-stage clinical development for treatment of B cell malignancies is blinatumomab (MT103 …
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
Curran E, Stock W. Curran E, et al. Blood. 2019 Apr 18;133(16):1715-1719. doi: 10.1182/blood-2018-12-852376. Epub 2019 Feb 22. Blood. 2019. PMID: 30796026 Free PMC article. Review.
Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and rec
Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leuk
523 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page